ClinicalTrials.gg
WithdrawnNCT06643143Updated Jun 13, 2025

A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of IkT-001Pro and Placebo in Pulmonary Arterial Hypertension (PAH) and Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), sponsored by Inhibikase Therapeutics. Withdrawn. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Inhibikase Therapeutics · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Study has undergone sponsorship and design changes.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy. It will enroll approximately 150 participants at up to 50 sites globally. The study consists of two parts, a 26 week placebo controlled treatment period (Part A) followed by a 36 month extension period (Part B).

Read the detailed description

This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH. This study will enroll approximately 150 participants at up to 50 sites globally.

The study consists of two parts, a 26 week placebo controlled treatment period (Part A) followed by a 36 month extension period (Part B). Those participants that pass the screening process will be randomized during the baseline visit to either the low dose (300mg) or placebo in a 2:1 ratio.

After two weeks participants will return to the clinic; upon confirmation that the participants are tolerating their dose, those that are on active treatment will be randomized to either 300mg or 500mg active treatment arms in a 1:1 manner. Those participants on placebo will remain on placebo for the rest of the 26-week placebo controlled treatment period. The final randomization structure for the 26-week placebo controlled treatment period will be such that participants are randomized in a 1:1:1 scheme to the 300 mg, 500 mg or placebo groups.

Participants who have not discontinued early will transition to a 36 month extension period. Participants who transition to the extension period will remain on the dose that they were assigned to after the two week acclimation period. Participants who were randomized to the placebo group will be re-randomized 1:1 to either the 300mg or 500mg IkT-001Pro treatment groups. The study will be unblinded and investigators will be given treatment assignments once the primary endpoint analysis is completed.

02

Conditions studied

  • Pulmonary Arterial Hypertension (PAH)
  • Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Keywords

  • Pulmonary Arterial Hypertension
  • PAH
03

In context

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Inhibikase Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women between the ages of 18 and 70 years of age (inclusive) at the time of signing the .
  2. Capable of giving signed ICF.
  3. Documented diagnostic right heart catheterization (RHC) at any time prior to screening confirming the diagnosis of WHO PAH Group 1 in any of the following subtypes:

    1. Idiopathic PAH
    2. Heritable PAH
    3. Drug/toxin-induced PAH
    4. PAH associated with CTD
    5. PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair
  4. Symptomatic PH classified as WHO FC II or III
  5. Baseline RHC performed during the Screening Period documenting a minimum PVR of

    ≥ 400 dyn.sec.cm-5 (≥5 WU) and a pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure of ≤ 15 mmHg.

    a. NOTE: At least 50% of study population needs to have PVR ≥ 800 dyn.sec.cm-5.

  6. On stable doses of background PAH therapy (i.e., patient-specific dose goal for each therapy already achieved) for at least 90 days prior to screening; for infusion prostacyclins, dose adjustment within 10% of optimal dose is allowed per medical practice.

    a. For those taking sotatercept their dosing regimen should be stable for at least 6 months prior to screening

  7. 6MWD ≥ 150 and ≤ 500 m repeated twice at screening (measured at least 4 hours apart, but no longer than 1 week), and both values are within 15% of each other (calculated from the highest value).

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of PAH WHO Groups 2, 3, 4, or 5
  2. Diagnosis of the following PAH Group 1 subtypes: (HIV)-associated PAH and PAH associated with portal hypertension. Exclusions in PAH Group 1 should also include schistosomiasis-associated PAH and pulmonary veno-occlusive disease
  3. Uncontrolled systemic hypertension as evidenced by sitting systolic BP > 160 mmHg or sitting diastolic BP > 100 mmHg during screening visit after a period of rest
  4. Personal or family history of long syndrome (LQTS) or sudden cardiac death
  5. Pulmonary function tests (PFT) completed no more than 24 weeks before the screening period (or completed at the Screening Visit). Following criteria must are considered exclusionary
  6. Cerebrovascular accident within 3 months prior to the screening visit
  7. Currently receiving moderate or strong Cytochrome P450 (CYP) 3A4/5 inducers or /5 inhibitors (except for topical administration)
  8. Currently receiving or anticipated need to receive anticoagulants
  9. Currently receiving or anticipated need to receive more than one anti- medication. The use of prostacyclins is not considered exclusionary. Note that sotatercept is not considered anti-platelet therapy
  10. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the screening visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
  11. History of atrial septostomy within 180 days prior to the screening visit
  12. Current participation in another clinical trial and/or receipt of any investigational medication within 90 days prior to screening
  13. Estimated (eGFR) \< 30 mL/min/m2 (as defined by the Modification of Diet in Renal Disease [MDRD] equation)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Placebo Control

    Placebo

    Drug: Placebo

  • Experimental
    300mg

    300mg

    Drug: IkT-001Pro

  • Experimental
    500mg

    500mg

    Drug: IkT-001Pro

Interventions

  • DrugIkT-001Pro

    IkT-001Pro

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. To evaluate the effect on PVR in participants with WHO functional class II-III PAH treated with IkT-001Pro compare to placebo

    Change in PVR at 26 weeks compared to baseline

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  2. To assess the safety and tolerability of two IkT-001Pro doses in PAH

    Incidence and temporal profile of treatment-emergent adverse events (TEAEs) evaluated by type/nature, severity/intensity, seriousness, and relationship to study intervention

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

Secondary outcomes

  1. To characterize the effects of two IkT-001Pro doses on symptoms and characterics of Pulmonary Arterial Hypertension

    Change from Baseline to Week 26 in 6 minute walk test.

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  2. To characterize the effects of two IkT-001Pro doses on symptoms and characterics of Pulmonary Arterial Hypertension

    Time to death or the first occurrence of any of the following clinical worsening events; Lung or heart-lung transplantation, Atrial septostomy, Hospitalization for worsening of PAH (≥ 24 hours) or Deterioration of PAH defined by both of the following events occurring at any time, even if they began at different times, as compared to their baseline values.

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  3. To characterize the effects of two IkT-001Pro doses on symptoms and characterics of Pulmonary Arterial Hypertension

    Number of participants who improve in WHO FC or who maintain or achieve a low risk score at Week 26 versus baseline using the ESC/ERS 4-strata model.

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  4. To assess the PK of IkT-001Pro in participants with PAH

    PK parameters of IkT-001Pro

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  5. Part B : To assess the long-term safety and tolerability of two IkT-001Pro doses in PAH

    Incidence and temporal profile of treatment-emergent adverse events (TEAEs) evaluated by type/nature, severity/intensity, seriousness, and relationship to study intervention

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  6. To characterize the effects of two IkT-001Pro doses on symptoms and characterics of Pulmonary Arterial Hypertension

    Change from Baseline to Week 26 in the Physical Impacts domain score of Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®)

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  7. To characterize the effects of two IkT-001Pro doses on symptoms and characterics of Pulmonary Arterial Hypertension

    Change from Baseline to Week 26 in the Cardiopulmonary Symptoms domain score of Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®)

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

  8. To characterize the effects of two IkT-001Pro doses on symptoms and characterics of Pulmonary Arterial Hypertension

    Change from Baseline to Week 26 in the Cognitive/Emotional Impacts domain score of Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®)

    Time frame: Through study completion, an average of 26 weeks with 36 months of extension

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Jun 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 16, 2024
StartEst.
Jun 30, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06643143
Lead sponsor
Inhibikase Therapeutics
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Jun 30, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion